Replies to post #28698 on Bioelectronics Corp (BIEL)

[zemun10]

FREDERICK, Md., March 11, 2013 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of unique inexpensive, patented, anti-inflammatory pain reliever devices announced that the OTC Bulletin, the leading global trade publication for over-the-counter healthcare products has chosen its ActiPatch® Musculoskeletal Pain Relief Therapy as the first runner-up for the "Most Innovative New OTC Product."
"We are pleased that this award illustrates the progress our team is making outside the US to establish ActiPatch® as a safe over-the-counter alternative to drugs," said Rick Staelin, chairman of the board of BioElectronics and the Edward and Rose Donnell Professor of Business Administration at The Fuqua School of Business, Duke University. "ActiPatch® Therapy meets a critical need for safe pain relief and it is now gaining recognition outside of the US. We appreciate the opportunity to participate in the OTC Awards and we are eager to submit our Allay™ Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy and other new products next year."
The OTC Bulletin is widely recognized as the most comprehensive trade publication for the consumer healthcare market in more than 45 countries. ActiPatch® Therapy placed second after Boots Pharmaceuticals Non-Contact Thermometer product.
A panel of six independent over-the-counter marketing experts evaluated all twelve nominees from some of the world's leading pharmaceutical companies. One of the judges, Jerome Reinsten, former Director-General of the World Self-Medication Industry, remarked that ActiPatch Therapy was a "novel and previously unexplored route to topical pain therapy," while another judge felt the product range was an "ingenious way of providing pain relief."
The complete details on the award winners are available in the 2013 OTC Awards Supplement http://www.otc-bulletin.com/awards/pdfs/WinnersSupplement2013.pdf.

[zemun10]

FREDERICK, Md., March 11, 2013 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of unique inexpensive, patented, anti-inflammatory pain reliever devices announced that the OTC Bulletin, the leading global trade publication for over-the-counter healthcare products has chosen its ActiPatch® Musculoskeletal Pain Relief Therapy as the first runner-up for the "Most Innovative New OTC Product."
"We are pleased that this award illustrates the progress our team is making outside the US to establish ActiPatch® as a safe over-the-counter alternative to drugs," said Rick Staelin, chairman of the board of BioElectronics and the Edward and Rose Donnell Professor of Business Administration at The Fuqua School of Business, Duke University. "ActiPatch® Therapy meets a critical need for safe pain relief and it is now gaining recognition outside of the US. We appreciate the opportunity to participate in the OTC Awards and we are eager to submit our Allay™ Menstrual Pain Therapy, Smart Insole™ Heel Pain Therapy and other new products next year."
The OTC Bulletin is widely recognized as the most comprehensive trade publication for the consumer healthcare market in more than 45 countries. ActiPatch® Therapy placed second after Boots Pharmaceuticals Non-Contact Thermometer product.
A panel of six independent over-the-counter marketing experts evaluated all twelve nominees from some of the world's leading pharmaceutical companies. One of the judges, Jerome Reinsten, former Director-General of the World Self-Medication Industry, remarked that ActiPatch Therapy was a "novel and previously unexplored route to topical pain therapy," while another judge felt the product range was an "ingenious way of providing pain relief."
The complete details on the award winners are available in the 2013 OTC Awards Supplement http://www.otc-bulletin.com/awards/pdfs/WinnersSupplement2013.pdf.

[Simpsonly]

To your comment about 2 to 3 cents being a touted exit price - IMO, if BIEL gets to 3 cents, it will get to a dime, or more, because it will have been a result of one or more of five reasons:
- real progress at the FDA creating optimism for timely OTC approval;
- a major retail chain in the US, or one of the other countries where it is already approved for OTC sale, adds it to its SKU listing;
- the founder gets out of his own way and the company announces a dynamic new CEO;
- Gro-International is successful, almost a month since that announcement; and
- a merger, or acquisition by a major player in the pharma or device spaces.

BIEL ran to 12 cents plus a few years ago on fictional rumor, if any 2 of the opportunities above become reality, I'm happy shareholders will win. As you essentially said, this is a company ready to leave the nest and fly. How many companies do not have the product line BIEL has?